# US 2025/0025479 A1 · Transpore delivery of steroids and large molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0025479 A1
- Document ID: US20250025479A1
- Status: Published application
- Kind: A1
- Application number: 18/581,836
- Filed: 2024-02-20
- Published: 2025-01-23
- Earliest claimed: 2018-09-28
- Inventors: Joel STUDIN
- Web page: https://patentgrep.com/patent/US20250025479A1

## CPC

- A61K 9/7015: {Drug-containing film-forming compositions, e.g. spray-on}
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/381: having five-membered rings
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C07K 16/241: {Tumor Necrosis Factors}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods of treatment involving transpore delivery of an active ingredient are provided.

## Claims

### Claim 1

A method for transpore delivery of a steroid to a patient suffering from a skin condition, the method comprising applying a liquid composition comprising about 1% to about 10% by weight of said steroid to an area of affected skin surface of the patient,
said composition, when applied to the skin surface of the patient, achieves one or more of the following: (a) has a thickness of about 0.1 μm to about 10 μm in solid or semi-solid form, (b) forms a solid or semi-solid film, and (c) provides a mean Tmax of from about 0.5 hours to about 8 hours,
wherein said composition seeps into skin pores in liquid form and creates a biomechanical integration with the interior of said skin pores in solid form, and
wherein said skin condition is selected from the group consisting of inflammatory skin conditions, hypertrophic scars, keloid scars, or a combination thereof.

### Claim at position 2

-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein said composition further comprises about 0% to about 9% by weight of silicone gel.

### Claim 11 (depends on 1)

The method of claim 1, wherein said composition further comprises about 50% to about 99% by weight of pyroxylin, ether and alcohol.

### Claim 12 (depends on 1)

The method of claim 1, wherein said skin condition is an inflammatory skin condition.

### Claim 13 (depends on 1)

The method of claim 1, wherein said skin condition is hypertrophic scars.

### Claim 14 (depends on 1)

The method of claim 1, wherein said skin condition is keloid scars.

### Claim 15 (depends on 1)

The method of claim 1, wherein said steroid is selected from the group consisting of one or more of clobetasol propionate, flurandrenolide, betamethasone dipropionate, diflorasone diacetate, desoximetasone, halobetasol propionate, fluocinonide, mometasone furoate, mometasone, halcinonide, desoximetasone, fluticasone propionate, triamcinolone acetonide, hydrocortisone valerate, fluocinolone acetonide, prednicarbate, desonide, hydrocortisone, fluocinolone acetonide, hydrocortisone valerate, alclometasone dipropionate, and other pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein said steroid is mometasone or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein about 0.5 mg to about 10 mg of said steroid is applied on to the affected skin surface in a daily dose.

### Claim 18 (depends on 1)

The method of claim 1, wherein about 0.05 ml to about 5 ml of said composition is applied on to the skin surface in a daily dose.

### Claim at position 12

-21. (canceled)

### Claim 22

A liquid composition comprising pyroxylin, ether, alcohol, and about 1% to about 10% by weight of steroid, said composition, when applied to an area of affected skin surface of a patient suffering from a skin condition, achieves one or more of the following: (a) has a thickness of about 0.1 μm to about 10 μm in solid form, (b) forms a solid or semi-solid film, and (c) provides a mean Tmax of from about 0.5 hours to about 8 hours.

### Claim 23

(canceled)

### Claim 24 (depends on 22)

The composition of claim 22, wherein the steroid is mometasone or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 22)

The composition of claim 22, wherein said composition seeps into skin pores in liquid form and creates a biomechanical integration with the interior of said skin pores in solid form.

### Claim at position 17

-29. (canceled)

### Claim 30 (depends on 22)

A method of treating a patient suffering from a skin condition, the method comprising applying the composition of claim 22 to an area of affected skin surface of the patient,
wherein said area of skin surface is from about 1 cm2 to about 500 cm2, and wherein said skin condition is selected from the group consisting of inflammatory skin conditions, hypertrophic scars, and keloid scars, or a combination thereof.

### Claim 31 (depends on 30)

The method of claim 30, wherein said skin condition is an inflammatory skin condition.

### Claim 32 (depends on 30)

The method of claim 30, wherein said skin condition is hypertrophic scars.

### Claim 33 (depends on 30)

The method of claim 30, wherein said skin condition is keloid scars.

### Claim at position 22

-83. (canceled)

### Claim 84

A liquid composition comprising about 0.001% to about 15% of an active ingredient by weight, about 0% to about 9% of silicone gel by weight, pyroxylin, ether, and alcohol, said composition, when applied to the skin surface of a patient, seeps into skin pores in liquid form and creates a biomechanical integration with the interior of said skin pores in solid form.

### Claim at position 24

-86. (canceled)

### Claim 87 (depends on 84)

The composition of claim 84, wherein said active ingredient is a steroid or an anesthetic.

### Claim at position 26

-98. (canceled)
